◈ Nootpedia
Compact view
Research pass: thorough Peptide · Injectable SKIP-FOR-NOW HIGH

IGF-1 (Insulin-like Growth Factor 1)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Supraphysiologic IGF-1 in a 20-year-old with peak endogenous IGF-1, plus mitogenic/cancer signaling concern, plus severe-hypoglycemia risk, plus brain-development concerns (IGF-1R is active in adult neurogenesis but supraphysiologic dosing is unstudied in young healthy men) = clear net-negative. Verdict would change ONLY for documented severe primary IGF-1 deficiency (Laron syndrome / SPIGFD) — biologically incompatible with Dylan's profile.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload, MMA athlete with peak endogenous IGF-1 (Dylan-archetype)
    SKIP-AT-

    HIGH confidence. No documented IGF-1 deficiency, peak natural IGF-1 (typical 200-400 ng/mL at 20yo), no body-comp gap that justifies a mitogenic anabolic peptide, plus brain-priority framing makes the cancer / cardiomyopathy / hypoglycemia risk profile absolutely unjustifiable. Brain development concerns specifically: IGF-1R signaling is active in adult hippocampal neurogenesis and prefrontal maturation continues into mid-20s; supraphysiologic IGF-1 effects on this process are unstudied in young healthy men, and the precautionary case strongly favors skip.

  • 20-30 with documented severe primary IGF-1 deficiency / Laron syndrome
    APPROPRIATE

    Rx (Increlex) under endocrinology supervision. Biologically vanishingly rare in untreated young adults — typically diagnosed in childhood from growth failure. Not Dylan's situation.

  • 30-50, executive maintenance
    SKIP

    No indication; cancer risk + cardiomyopathy risk + hypoglycemia outweigh marginal body-comp gains.

  • 50+, mild cognitive decline
    SKIP

    While IGF-1 has plausible neurogenesis support roles and low circulating IGF-1 correlates with poor cognitive aging, exogenous supraphysiologic IGF-1 administration has never demonstrated cognitive preservation in trials and the cancer-promotion concern actively rises in this age band.

  • Anxiety-prone
    SKIP

    Hypoglycemia symptoms overlap with panic/anxiety presentation; not a fit.

  • High athletic load, tested status (NCAA, USADA, WADA, professional combat sport)
    SKIP-PERMANENT

    during testing window — S2 banned, detectable.

  • High athletic load, untested status
    SKIP

    as default; the risk profile (severe hypoglycemia + cancer + cardiomyopathy) is independent of testing status.

  • Sleep-disordered
    SKIP

    Address sleep first; IGF-1 has no role here.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    for healthy young. For specific sarcopenia / catabolic states (chronic kidney disease, severe burn, HIV wasting), IGF-1 has investigational uses under medical supervision — not Dylan's situation. BPC-157 / TB-500 (Dylan's active peptide thread for cubital tunnel) are far better-fit for localized injury recovery without systemic mitogenic loading.

  • Strength/anabolic-focused, healthy young eugonadal
    SKIP

    Brief body-comp wins do not outweigh the risk constellation. Compatible with the broader "skip-at-20 anabolic family" verdict (also: CJC-1295, ipamorelin, MK-677, tesamorelin, follistatin, SARMs, AAS).

▸ Subjective experience (deep)

At bodybuilder doses (LR3 20-50 mcg/day or DES 50-150 mcg/injection)

  • Acute (within 30-90 min of injection): Hypoglycemia symptoms — lightheadedness, shakiness, sweating, fatigue, blurred vision, hunger pangs. Severity ranges from mild (managed with oral glucose) to severe (loss of consciousness, seizures reported in fasted high-dose injections). Site-of-injection mild swelling possible.
  • Within hours-days (LR3 specifically, given long half-life): Subjective "fullness," visible muscle pump persisting beyond workout window, increased appetite, occasional fluid retention, mild edema in extremities or face.
  • Cycle-scale (6-12 weeks): Mild lean mass increase, modest fat loss in some users, "soft" appearance (water + glycogen). Some users report joint pain, jaw discomfort, hand/foot tingling (carpal tunnel-like, mirroring acromegaly soft-tissue overgrowth).
  • Chronic / repeated cycles: Mounting concern — bodybuilding forums document users with acromegaly-like jaw protrusion, brow ridge prominence, hand/foot enlargement after years of GH+IGF-1 stacking. Direct causal attribution to IGF-1 alone vs. concomitant GH or insulin is hard but the soft-tissue overgrowth pattern is consistent with chronic GH/IGF-1 axis loading.

At Increlex / mecasermin therapeutic doses (pediatric SPIGFD)

  • Hypoglycemia risk — primary clinical concern, requires meal coordination
  • Tonsillar / adenoidal hypertrophy — common, occasionally requires surgical management
  • Growth velocity increase — the therapeutic effect, gradually visible over months
  • Local injection-site reactions, occasional hypersensitivity / anaphylaxis (rare)
  • Intracranial hypertension (papilledema, headache, visual changes) — uncommon but documented, mirrors GH-class side effect profile
  • Slipped capital femoral epiphysis, scoliosis progression — bone/skeletal side effects in growing children
▸ Tolerance + cycling deep dive
  • Tolerance buildup: Receptor downregulation reported with chronic supraphysiologic exposure; functional tolerance to anabolic effects develops over weeks-months in many users; metabolic / hypoglycemic potency typically persists. Variable.
  • Recommended cycle (bodybuilder convention): 4-6 weeks on, equal off. Convention only — no clinical trial backing.
  • Reset protocol: Off-cycle 4-12 weeks; HPG / GH axis is not directly suppressed by IGF-1 (unlike CJC/Ipamorelin/MK-677, which act via the GH pulse), but feedback on hypothalamic GHRH does occur — IGF-1 feeds back negatively on GH secretion. So extended IGF-1 administration can blunt endogenous GH release. Recovery typically rapid (weeks) on cessation.
▸ Stacking deep dive

Synergistic with (in bodybuilder protocols, NOT recommended for Dylan)

  • GH (somatropin): Raises IGF-1 endogenously and potentiates IGF-1's anabolic effects; canonical "GH+IGF-1" stack. Compounds cardiomyopathy, organomegaly, cancer-promotion risk.
  • Insulin: Used by competitive bodybuilders for nutrient partitioning; dramatically amplifies hypoglycemia risk to potentially fatal levels. Repeatedly implicated in bodybuilder deaths.
  • Anabolic-androgenic steroids (AAS): Synergistic for muscle growth; classic "GH/IGF/insulin/AAS" stack of competitive bodybuilding; full constellation of HPG suppression + cardiomyopathy + cancer risks.

Avoid stacking with

  • Other GH-axis peptides (CJC-1295, ipamorelin, hexarelin, MK-677, tesamorelin): Compounds GH/IGF-1 axis loading; redundant + risk-stacking.
  • Insulin / oral hypoglycemics: Severe hypoglycemia risk (life-threatening).
  • Sulfonylureas: Same.
  • Beta blockers in non-cardio-protective doses: May mask hypoglycemia warning signs (sweating, tachycardia).

Neutral / safe co-administration

  • Most non-hormonal nootropics (modafinil, citicoline, NAC, magnesium, fish oil, etc. — Dylan's V4) — no direct interaction; the issue is not pharmacological collision but the underlying inappropriateness of IGF-1 dosing.
▸ Drug interactions deep dive
  • Insulin and oral hypoglycemic agents: Major interaction — additive hypoglycemia risk, may require insulin dose reduction. Critical clinical concern in any diabetic patient.
  • Glucocorticoids: Antagonize IGF-1's anabolic effects and modulate axis; chronic steroid use is a contraindication for mecasermin.
  • GH (somatropin): Synergistic (mecasermin label notes); stacking is intentional in some endocrine indications and bodybuilding contexts but compounds risk.
  • CYP-mediated metabolism: Minimal — IGF-1 is a peptide, cleared primarily via receptor-mediated clearance, peptidase degradation, and renal pathways; not a CYP450 substrate. No major CYP drug interactions.
  • Detection (WADA): IGF-1 and synthetic analogs are S2 (Peptide Hormones, Growth Factors, Related Substances) on the WADA Prohibited List, banned in- and out-of-competition. Detection methods include serum IGF-1 + IGFBP-3 ratio analysis, isotope ratio mass spectrometry, and direct LC-MS/MS for synthetic-specific epitopes. Irrelevant for Dylan's untested status.
▸ Pharmacogenomics
  • IGF1 gene polymorphisms affect baseline circulating IGF-1 levels. Dylan's 23andMe (June 2026) will likely include some IGF1 SNPs but no clinical pharmacogenomic dosing guidance exists for exogenous IGF-1.
  • IGF1R polymorphisms affect receptor density / signaling sensitivity. Investigated in cancer pharmacogenomics, not in performance dosing.
  • GH1 / GHR polymorphisms affect endogenous GH-IGF-1 axis tone. Relevant for true GH/IGF-1 deficiency workup, not bodybuilder dosing.
  • Practical note: No pharmacogenomic test changes the SKIP-AT-20 verdict. Verdict is driven by the indication / risk balance, not metabolic variability.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Rx (US) — Increlex / mecasermin Eton Pharmaceuticals (acquired from Ipsen 2024) via specialty pharmacy ~$30,000-100,000+/year (pediatric weight-based) High (legitimate biologic Rx) Indicated only for severe primary IGF-1 deficiency in pediatrics; adult use off-label and not insured; not clinically obtainable for Dylan
Gray-market research-chem SwissChems, Peptide Sciences, Edge Peptides, Umbrella Labs, Nova Peptide Supply, etc. (LR3 1mg vials) $35-245/vial; budget bulk ~$59/vial (10-pack) to premium ~$245/vial Low-to-medium Marketed "for research use only — not for human consumption"; quality varies dramatically; COA verification critical; reconstitution + dosing math + cold-chain handling all on user; counterfeit / underdosed product common
Gray-market research-chem Same vendors offer DES (typically 1mg vials, similar pricing tier) ~$60-150/vial Low-to-medium Same caveats
International / Indian pharmacy Limited availability for native rhIGF-1; primarily sourced as research chem Varies Low Not the typical sourcing channel for IGF-1 specifically

For Dylan: Sourcing is solvable (research-chem vendors trivially accessible), but sourcing is not the gating question — appropriateness is. Skip the compound, do not engage the sourcing question.

▸ Biomarkers to track (deep)
  • Baseline (before starting): Serum IGF-1 (LC-MS/MS), IGFBP-3, fasting glucose, fasting insulin, HOMA-IR, HbA1c, GH (random + stim if borderline), TSH/fT4, prolactin, total/free T, LH/FSH, CBC, CMP (LFTs), lipid panel, PSA (if >40), echocardiogram baseline (especially for chronic intent), eye exam (papilledema baseline)
  • During use: IGF-1 + IGFBP-3 every 4-6 weeks (target should NOT exceed ~1.5× upper limit of age-adjusted normal); fasting glucose + HOMA-IR weekly initially; HbA1c at week 12; CBC + LFTs + lipids at week 12; symptom diary (hypoglycemia events, jaw / hand / foot changes, vision, headache, joint pain)
  • Post-cycle: IGF-1 + IGFBP-3 4 weeks post-stop to confirm normalization; glucose homeostasis re-check
  • Long-term (years of cyclic use): Annual cancer screening proportionate to age + risk; periodic echocardiogram; baseline mammogram / prostate / colorectal screening earlier than otherwise indicated
▸ Controversies / open debates Live debate

1. The "localized growth" myth (LR3 / DES injection-site claim)

Claim circulating in bodybuilding literature: "IM injection of IGF-1 LR3 or DES into a target muscle (biceps, calves, lagging body part) produces localized hyperplasia at that muscle, without systemic effects."

Reality after deep mechanistic review:

  • Once injected into interstitial space, IGF-1 (LR3 or DES) distributes systemically via lymphatic + capillary uptake. There is no peptide that "stays localized" once it leaves the depot phase. The depot half-life at the injection site is on the order of minutes to hours.
  • The "site receptor saturation" argument has limited merit at very brief windows (DES's ~20-30 min half-life means injection-site interstitial concentration is briefly very high), but for LR3 with a 20-30 hour half-life, the molecule is overwhelmingly systemic for the bulk of its activity window.
  • Satellite cell proliferation at the injection site is real but is not exclusively local — systemic IGF-1 elevation drives satellite cell activity throughout muscle tissue.
  • The cardiomyopathy, cancer, and hypoglycemia concerns are driven by systemic IGF-1 elevation, which occurs whether you inject in the arm or the abdomen or anywhere else. "Site injection" does not mitigate the systemic risk profile.
  • Bodybuilder anecdote of "I injected my biceps and got bigger biceps" is consistent with systemic anabolic effect localized to the muscles being trained — i.e., training stimulus + systemic IGF-1 → local muscle growth. The same growth would occur with a different injection site if biceps were the trained muscle. This is not a localization phenomenon, it's a use-dependent systemic phenomenon being misattributed.

Verdict on the localized-growth claim: Mostly myth. There is brief injection-site receptor activation (especially with DES), but no escape from systemic distribution and systemic risk. Marketing-grade overstatement.

2. Is supraphysiologic IGF-1 actually causal for cancer, or just permissive?

The most rigorous current scientific consensus: circulating IGF-1 has a permissive effect on existing cancers but is not solely causal in initiation. High IGF-1 at the time of malignant transformation accelerates clonal expansion + suppresses apoptosis in transformed cells, raising probability of clinically apparent cancer. It does not, by itself, transform a healthy cell to malignant.

For Dylan at 20yo, this means:

  • Subclinical micrometastases / pre-malignant lesions exist at low rates even in young adults (testicular, melanoma, lymphoma have notable young-adult incidence)
  • Supraphysiologic IGF-1 elevates the permissive environment for any such lesion
  • The conditional risk of accelerating an undetected malignancy is non-zero and the upside is body composition

The risk/benefit math is straightforwardly unfavorable.

3. Bodybuilder dose vs. acromegaly dose comparison

A common bodybuilder talking point: "Acromegaly is chronic 24/7 supraphysiologic GH/IGF-1 over decades; my 6-week cycle of LR3 isn't comparable." Partially true, partially false:

True: A 6-week cycle does not produce the cumulative cardiomyopathy / organomegaly burden of a 20-year acromegaly course. Acute cycles are different from chronic disease.

False: Bodybuilder use of IGF-1 is rarely a single 6-week cycle — typical practitioners cycle multiple times per year for years. Cumulative exposure approaches chronic acromegaly-like loading at 5-10+ year careers. The cardiomyopathy + cancer associations of chronic GH/IGF-1 axis loading apply with cumulative dose-time, not just peak level.

The person who runs "just one cycle and then never again" is rare; the typical user accumulates exposure over years.

4. Increlex availability + ownership

October 2024: Eton Pharmaceuticals announced acquisition of Increlex from Ipsen, with continuity of supply. As of 2025, Increlex remains the only FDA-approved mecasermin product. Pricing remains in the $30-100k+/year range for pediatric Rx — not a meaningful gray-market alternative path; bodybuilders virtually exclusively use research-chem LR3 / DES.

5. Is "low IGF-1 of aging" an indication?

No. This is a periodic claim from anti-aging clinics — that age-related IGF-1 decline (from peak ~250 ng/mL at 20yo to ~100-150 ng/mL at 60yo) merits IGF-1 replacement. The clinical literature does not support this:

  • Low IGF-1 in older adults is associated with decreased cancer risk (e.g., the Laron-syndrome population shows near-zero cancer rates)
  • Long-lived populations (centenarians, IGF-1R signaling-attenuated mice) have lower IGF-1 axis tone, not higher
  • The "anti-aging IGF-1 replacement" framing is squarely against the longevity literature

For Dylan's longevity priority, this is not a candidate.

▸ Verdict change log
  • 2026-05-04 (Encyclopedia v5) — SKIP-AT-20, listed in GH-axis / anabolic peptide skip-at-20 family with brief mechanism + risk note.
  • 2026-05-05 (this file, deep research) — SKIP-AT-20 HIGH confidence. Affirmed and deepened. Mechanism + evidence + side-effect profile + bodybuilder claim audit + brain-development concern all reviewed; no plausible benefit case for healthy 20yo with peak endogenous IGF-1; multiple independent risk vectors (severe hypoglycemia, cancer permissivity, cardiomyopathy risk in chronic exposure, brain-development unstudied) converge. The "localized growth" claim driving LR3/DES popularity is largely myth. Verdict reverses ONLY for documented severe primary IGF-1 deficiency under endocrinology supervision (clinically implausible in Dylan).
▸ Open questions / gaps Open
  • Long-term safety of supraphysiologic IGF-1 in healthy young adult men: No RCT data; observational + extrapolation from acromegaly only.
  • Brain development effects of supraphysiologic IGF-1 in 20-25yo (prefrontal maturation window): Unstudied. IGF-1R is active in adult neurogenesis but supraphysiologic loading effects unknown — precautionary case favors skip.
  • Cumulative cancer risk from cyclic bodybuilder dosing over decades: No prospective data; epidemiologic association from acromegaly + Mendelian randomization studies of high-IGF-1 phenotypes suggests real risk but quantification is poor.
  • Whether DES's short half-life genuinely produces an injection-site-only effect at any meaningful magnitude: Mechanistically plausible at the very-short-window margin, not validated in human imaging / biopsy data.
  • Whether IGF-1 LR3 has any cognitive / neurogenic upside that could partially offset the risk profile: Single negative study in 5XFAD mouse model (intranasal, 2025) suggests no easy cognitive wins; the broader mouse / cell-culture literature is positive but unreplicated in clinical trials.
  • What documented IGF-1 deficiency would look like in Dylan's bloodwork (June 2026): IGF-1 <80 ng/mL (or below age-adjusted lower limit of normal) with low IGFBP-3, normal GH, plus growth-failure history — biologically extremely unlikely at 20yo without prior diagnosis.
▸ Sources (full, with our context)
Back to compact view